The Official Medicare Set Aside Blog And Information Resource

FDA Approves First Ibuprofen-Acetaminophen Combination Product

FDA, Medicare Set-Aside Blog, Rx/Pharmacy on May 5, 2020
Posted by Leah King, PharmD, JD, Independent Pharmacy Consultant

The FDA has approved the first ibuprofen-acetaminophen combination product, which will be available as an over-the-counter product and marketed under the name of Advil Dual Action. The use of Advil Dual Action is approved for the temporary relief of minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches and minor pain […] Continue

DEA Temporarily Lifts Restrictions for Controlled Substances

Medicare Set-Aside Blog, Opioids, Rx/Pharmacy on April 29, 2020
Posted by Leah King, PharmD, JD, Independent Pharmacy Consultant

The COVID-19 pandemic has provoked a variety of responses from the federal government in addition to nearly every state government. On January 31, 2020, the Secretary of HHS declared a public health emergency due to COVID-19. In turn, this declaration prompted the DEA to identify steps it could take to ensure the public’s continued access […] Continue

Announcing: MEDVAL Rx for Self-Administered MSAs

Medicare Set-Aside Blog, Medicare Set-Asides, MSA Administration, Rx/Pharmacy on April 23, 2020
Posted by Jean S. Goldstein, JD, CMSP

MEDVAL is pleased to announce its new Post-Settlement Administration Services offered through MEDVAL Rx. These services are available to individuals who have funds in a Medicare-Set-Aside (MSA) account to pay for future prescription expenses.  MEDVAL Rx historically limited these services to MSAs that were professionally administered, but all self-administered MSA accounts, regardless of which vendor […] Continue

COVID-19: Impact on the FDA Pipeline

FDA, Medicare Set-Aside Blog, Rx/Pharmacy on April 15, 2020
Posted by Leah King, PharmD, JD, Independent Pharmacy Consultant

The impact of COVID-19 has undoubtedly been profound, but some of its effects are less obvious than others. One of the impacts associated with the COVID-19 pandemic that may not have hit home yet for many is the likely effect on the pipeline of new drug approvals through the FDA. The pandemic will likely produce […] Continue

Significant Price Changes for Meloxicam & Benefits to Your WCMSAs

Medicare Set-Aside Blog, MSAs, Rx/Pharmacy on April 2, 2020
Posted by Jean S. Goldstein, JD, CMSP

Mobic (meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) commonly seen in workers’ compensation claims.  It is most frequently prescribed to treat osteoarthritis (OA) starting at doses of 7.5 mg and may be increased to 15 mg daily to reduce pain, joint swelling, and stiffness in joints. Recently, the average wholesale price of this medication dropped […] Continue